oncology
Medicines

Duration of checkpoint inhibitor treatment the next milestone

Australian patients with metastatic melanoma will be among those helping to determine the optimal duration of treatment with immune checkpoint inhibitors (ICIs). A prospective trial recruiting across multiple sites in Australia and Canada will compare continuous versus intermittent therapy with any approved and publicly funded PD-1 inhibitor. STOP-GAP is just one of a number of ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic